- Home
- SGN vs PTIX Comparison
SGN vs PTIX Comparison
Compare SGN & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- PTIX
- Stock Information
- Founded
- SGN 2019
- PTIX 1994
- Country
- SGN United States
- PTIX United States
- Employees
- SGN N/A
- PTIX N/A
- Industry
- SGN
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- SGN
- PTIX Health Care
- Exchange
- SGN Nasdaq
- PTIX Nasdaq
- Market Cap
- SGN 2.4M
- PTIX 2.0M
- IPO Year
- SGN 2023
- PTIX 2016
- Fundamental
- Price
- SGN $2.18
- PTIX $0.27
- Analyst Decision
- SGN
- PTIX
- Analyst Count
- SGN 0
- PTIX 0
- Target Price
- SGN N/A
- PTIX N/A
- AVG Volume (30 Days)
- SGN 8.2M
- PTIX 599.7K
- Earning Date
- SGN 03-28-2025
- PTIX 03-31-2025
- Dividend Yield
- SGN N/A
- PTIX N/A
- EPS Growth
- SGN N/A
- PTIX N/A
- EPS
- SGN N/A
- PTIX N/A
- Revenue
- SGN $576,488.00
- PTIX N/A
- Revenue This Year
- SGN N/A
- PTIX N/A
- Revenue Next Year
- SGN N/A
- PTIX N/A
- P/E Ratio
- SGN N/A
- PTIX N/A
- Revenue Growth
- SGN 147.76
- PTIX N/A
- 52 Week Low
- SGN $1.75
- PTIX $0.25
- 52 Week High
- SGN $36.72
- PTIX $1.87
- Technical
- Relative Strength Index (RSI)
- SGN 42.84
- PTIX 34.94
- Support Level
- SGN $2.04
- PTIX $0.25
- Resistance Level
- SGN $2.49
- PTIX $0.30
- Average True Range (ATR)
- SGN 0.38
- PTIX 0.03
- MACD
- SGN -0.04
- PTIX 0.00
- Stochastic Oscillator
- SGN 8.43
- PTIX 10.43
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.